The stock price of TransCode Therapeutics Inc (NASDAQ: RNAZ) has dropped by -23.58 compared to previous close of 0.36. Despite this, the company has seen a fall of -31.64% in its stock price over the last five trading days. zacks.com reported 2025-04-18 that TransCode Therapeutics (RNAZ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is It Worth Investing in TransCode Therapeutics Inc (NASDAQ: RNAZ) Right Now?
Additionally, the 36-month beta value for RNAZ is 1.56. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for RNAZ is 20.98M and currently, short sellers hold a 12.17% ratio of that float. The average trading volume of RNAZ on April 21, 2025 was 7.44M shares.
RNAZ’s Market Performance
The stock of TransCode Therapeutics Inc (RNAZ) has seen a -31.64% decrease in the past week, with a -64.14% drop in the past month, and a -91.87% fall in the past quarter. The volatility ratio for the week is 22.24%, and the volatility levels for the past 30 days are at 23.95% for RNAZ. The simple moving average for the past 20 days is -45.74% for RNAZ’s stock, with a -97.30% simple moving average for the past 200 days.
RNAZ Trading at -91.47% from the 50-Day Moving Average
After a stumble in the market that brought RNAZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.59% of loss for the given period.
Volatility was left at 23.95%, however, over the last 30 days, the volatility rate increased by 22.24%, as shares sank -64.61% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -96.95% lower at present.
During the last 5 trading sessions, RNAZ fell by -31.64%, which changed the moving average for the period of 200-days by -99.14% in comparison to the 20-day moving average, which settled at $0.5023. In addition, TransCode Therapeutics Inc saw -91.91% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for RNAZ
Current profitability levels for the company are sitting at:
- -19.47 for the present operating margin
- 0.44 for the gross margin
The net margin for TransCode Therapeutics Inc stands at -19.82. The total capital return value is set at -8.88. Equity return is now at value -490.03, with -268.85 for asset returns.
Based on TransCode Therapeutics Inc (RNAZ), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -103.97. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is -181.32.
When we switch over and look at the enterprise to sales, we see a ratio of 6.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.56.
Conclusion
In conclusion, TransCode Therapeutics Inc (RNAZ) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high..
